Milford, Ohio, United States
Service members and veterans live with conditions — phantom limb pain, autonomic dysfunction, sleep disruption, chronic fatigue — that existing military health programs monitor but cannot treat at the point of need. That problem is why I do what I do. I'm COO and Regulatory Compliance Officer at OptiRTP Limited, leading U.S. market entry for OBST (Optimum Bio Sound Therapy) — an FDA registered Class I medical device that delivers precision acoustic input through the auditory pathway to engage brainstem autonomic circuits. No drugs, no implants, no surgical intervention. 510(k) exempt. It can enter the military health pathway today. 352,393 documented therapy hours. Zero serious adverse events. Eight measurable therapeutic domains — sleep, autonomic function, pain, fatigue, biomarkers, medication use, quality of life, and treatment adherence — all emerged from real-world data, not hypothesis. Those domains were validated by elite athletes, the most precisely monitored humans in the world, then mapped against the same domains the Department of War already tracks through $337 million in wearable biometric programs. A VA phantom limb pain clinical trial has been fully designed and costed with Lindus Health as CRO. That trial generates the clinical evidence for De Novo reclassification to Class II neuromodulation with prescription status — which unlocks pharmaceutical co-therapy partnerships addressing the 21–25% of cancer patients who stop immunotherapy and chemotherapy because the side effects become unbearable. OptiRTP is New Zealand-headquartered with a U.S. Delaware C-Corp. TAA-compliant American manufacturing in development. Permanent U.S. operations. Attending the 2026 SelectUSA Investment Summit. Member, Society for Integrative Oncology (SIO) — Research Committee focus. Outside of work, I can be found in my garden, and surrounded by dogs, cats, and a flock of chickens who answer to no one.